Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles filed under Research Updates.
Oral GLP-1 pills are trending as elecoglipron trial data raise a serious question: will tablets broaden access to GLP-1 weight-loss and diabetes therapy?
A new ENDO 2026 wearable-data study found GLP-1 users lost weight but moved less. Alex Keane explains why steps, resistance training, and muscle protection now matter.
GLP-1 cancer risk is suddenly a mainstream question. Alex Keane explains what the newest studies suggest, what they do not prove, and why peptide biology matters.
Oral GLP-1 pill elecoglipron is trending after new Phase 2 data. Here is what it means for peptide science, injections, and metabolic medicine.
The viral Ozempic lizard venom story points to real peptide science. Learn how exendin-4, exenatide, and semaglutide fit together.
Retatrutide search interest is rising alongside GLP-1 hype. Here is what the evidence says, what remains investigational, and why gray-market peptides are risky.
Peptide injections are suddenly everywhere in wellness culture. Here is how GLP-1 evidence differs from experimental stacks like BPC-157, MOTS-c, and TB-500.
GLP-1 drugs and retatrutide are suddenly part of the knee osteoarthritis conversation. Here is what the peptide science says, and what remains unproven.
Peptides are trending because GLP-1 drugs, retatrutide buzz, and research-use peptides have converged into one urgent health conversation.
Retatrutide phase 3 weight-loss results explained, including its triple GIP, GLP-1 and glucagon mechanism and why weight management matters for orthopedic patients.
Roche’s ADA 2026 obesity update puts enicepatide, petrelintide, and amylin-incretin combinations at the center of today’s weight-loss peptide conversation. Here is the cautious science behind the momentum.
BPC-157 is a promising peptide research topic with compelling preclinical signals, limited human evidence, and a changing FDA compounding-review context after the April 2026 Category 2 removal.
An updated explanation of the FDA’s April 2026 peptide reclassification, Category 2 removals, upcoming PCAC review, and what the changes may mean for compounding pharmacies and patients.
No articles match that search.